Sudarshan Pharma Industries Limited (BOM:543828)
India flag India · Delayed Price · Currency is INR
24.91
-0.38 (-1.50%)
At close: Mar 9, 2026

BOM:543828 Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2020 - 2016
Market Capitalization
5,9957,3501,784960--
Upgrade
Market Cap Growth
-28.87%312.09%85.79%---
Upgrade
Enterprise Value
8,1658,5732,0071,312--
Upgrade
Last Close Price
24.9130.547.415.56--
Upgrade
PE Ratio
29.8646.0715.5713.64--
Upgrade
PS Ratio
0.931.460.390.21--
Upgrade
PB Ratio
4.265.591.600.95--
Upgrade
P/TBV Ratio
4.465.761.670.96--
Upgrade
P/FCF Ratio
-24.3330.22---
Upgrade
P/OCF Ratio
-21.0618.41---
Upgrade
EV/Sales Ratio
1.271.700.430.28--
Upgrade
EV/EBITDA Ratio
17.5221.738.488.62--
Upgrade
EV/EBIT Ratio
17.8622.318.949.17--
Upgrade
EV/FCF Ratio
-28.3734.01---
Upgrade
Debt / Equity Ratio
1.561.300.940.341.031.32
Upgrade
Debt / EBITDA Ratio
4.694.334.432.242.784.08
Upgrade
Debt / FCF Ratio
-5.6517.76--20.26
Upgrade
Net Debt / Equity Ratio
1.541.280.920.221.021.26
Upgrade
Net Debt / EBITDA Ratio
4.644.284.361.472.763.91
Upgrade
Net Debt / FCF Ratio
-5.5817.49-0.52-5.5419.40
Upgrade
Asset Turnover
-1.471.802.493.022.46
Upgrade
Inventory Turnover
-3.895.277.109.478.69
Upgrade
Quick Ratio
-0.630.820.790.720.87
Upgrade
Current Ratio
-1.291.481.681.261.23
Upgrade
Return on Equity (ROE)
-13.12%10.77%10.76%20.06%12.60%
Upgrade
Return on Assets (ROA)
-7.01%5.44%4.83%5.36%5.28%
Upgrade
Return on Invested Capital (ROIC)
9.91%11.00%9.98%11.56%13.43%11.01%
Upgrade
Return on Capital Employed (ROCE)
-26.90%18.30%12.60%29.10%23.80%
Upgrade
Earnings Yield
3.50%2.17%6.42%7.33%--
Upgrade
FCF Yield
-4.11%3.31%-44.92%--
Upgrade
Dividend Yield
---0.54%--
Upgrade
Payout Ratio
--6.30%---
Upgrade
Buyback Yield / Dilution
-3.91%-1.30%0.83%-66.88%5.63%-
Upgrade
Total Shareholder Return
-3.91%-1.30%0.83%-66.34%5.63%-
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.